1Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China; 2Department of Radiation, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China
Abstract：Objective To conduct meta analysis to compare the effect of complete resection with or without postoperative radiotherapy (PORT) on survival in stage Ⅲ(N2) non-small cell lung cancer (NSCLC). Methods Relevant studies of the efficacy of PORT for stage Ⅲ(N2) NSCLC were searched from Wanfang Data, PubMed, and Cochrane Library from January 2006 to January 2022. Literature screening, extraction of information and assessment of the risk of bias of the included literature was carried out by two independent researchers. Meta analysis was performed using R4.0.3 software. Results A total of 12 publications consisting of 2992 patients were included, 1479 cases in the PORT group and 1513 cases in the control group. PORT improved the overall survival (OS) and disease free survival (DFS) compared to the control group. Fixed-effects model meta analysis of 6 randomized controlled trials showed that PORT did not significantly reduce the risk of death (HR=0.98, 95%CI: 0.80-1.20). Fixed-effects model meta analysis of 6 retrospective studies showed that PORT improved prognosis (HR=0.68, 95%CI: 0.59-0.79). PORT could improve OS of patients with multiple (station) metastasis of ipsilateral mediastinum and / or submandibular lymph nodes (HR=0.89, 95%CI: 0.80-0.99). Conclusions PORT could improve OS and DFS in stage Ⅲ(N2) NSCLC. A trend towards benefit can be observed in the subgroup with multiple/multi-station N2 metastasis.
Ling Lixian,Zhou Shishi,Zheng Hongjuan et al. The efficacy of postoperative radiotherapy in stage Ⅲ(N2) non-small cell lung cancer: a meta analysis[J]. Chinese Journal of Radiation Oncology, 2023, 32(4): 293-300.
[1] Arriagada R, Auperin A, Burdett S, et al.Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data[J]. Lancet, 2010,375(9722):1267-1277. DOI: 10.1016/S0140-6736(10)60059-1. [2] Robinson CG, Patel AP, Bradley JD, et al.Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base[J]. J Clin Oncol, 2015,33(8):870-876. DOI: 10.1200/JCO.2014.58.5380. [3] Mikell JL, Gillespie TW, Hall WA, et al.Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base[J]. J Thorac Oncol, 2015,10(3):462-471. DOI: 10.1097/JTO.0000000000000411. [4] Patel SH, Ma Y, Wernicke AG, et al.Evidence supporting contemporary post-operative radiation therapy (PORT) using linear accelerators in N2 lung cancer[J]. Lung Cancer, 2014,84(2):156-160. DOI: 10.1016/j.lungcan. 2014.02.016. [5] Hui ZG, Men Y, Hu C, et al.Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial[J]. JAMA Oncol, 2021,7(8):1178-1185. DOI: 10.1001/jamaoncol.2021.1910. [6] Shen WY, Ji J, Zuo YS, et al.Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial[J]. Radiother Oncol, 2014,110(1):120-125. DOI: 10.1016/j.radonc.2013.10.008. [7] Le Pechoux C, Pourel N, Barlesi F, et al.Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022,23(1):104-114. DOI: 10.1016/S1470-2045(2 1)00606-9. [8] Perry MC, Kohman LJ, Bonner JA, et al.A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734[J]. Clin Lung Cancer, 2007,8(4):268-272. DOI: 10.3816/CLC.2007.n.005. [9] Sun JM, Noh JM, Oh D, et al.Randomized phase II trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer[J]. J Thorac Oncol, 2017,12(12):1806-1813. DOI: 10.1016/j.jtho.2017.09.1954. [10] 吴金通, 陈奇松, 沈芬, 等. IIIA-N2期NSCLC完全切除术后三维适形放疗联合辅助化疗与单纯辅助化疗的疗效对比观察[J]. 华西医学,2009,24(2):385-388. Wu, JT, Chen QS, Shen F, et al. Comparison of the outcome of complete excision followed by three-dimensional conformal radiation therapy and adjuvant chemotherapy versus adjuvant chemotherapy alone in the treatment of patients with stage IIIA-N2 non-small cell lung cancer[J]. West China Medical Journal,2009,24(2):385-388. [11] Yun JK, Lee GD, Choi S, et al.The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis[J]. Lung Cancer, 2021,155:94-102. DOI: 10.1016/j.lungcan.2021.03.011. [12] Xu YJ, Li JQ, Wang J, et al.Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer[J]. Oncol Lett, 2018,15(2):2641-2650. DOI: 10.3892/ol.2017.7601. [13] Wang T, Jiang T, Han Y, et al.Effects of postoperative adjuvant radiotherapy on stage IIIA-N2 non-small cell lung cancer and prognostic analysis[J]. J BUON, 2021,26(2):328-335. [14] Wei W, Zhou J, Zhang Q, et al.Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: a single-center, retrospective study[J]. Cancer Med, 2020,9(8):2820-2832. DOI: 10.1002/cam4.2937. [15] Brandt WS, Yan W, Leeman JE, et al.Postoperative radiotherapy for surgically resected ypN2 non-small cell lung cancer[J]. Ann Thorac Surg, 2018,106(3):848-855. DOI: 10.1016/j.athoracsur.2018.04.064. [16] Hui ZG, Men Y, Kang J, et al.Contemporary postoperative radiation therapy improves the survival of patients with resected pathological IIIA-N2 non-small cell lung cancer treated with adjuvant chemotherapy[J]. Inter J Radiat Oncol Biol Phys,2017,99(2): E463. DOI: 10.1016/j.ijrobp.2017.06.1709. [17] Herskovic A, Mauer E, Christos P, et al.Role of postoperative radiotherapy in pathologic stage IIIA (N2) non-small cell lung cancer in a prospective nationwide oncology outcomes database[J]. J Thorac Oncol, 2017,12(2):302-313. DOI: 10.1016/j.jtho.2016.09.135. [18] Duan HX, Liang L, Xie SS, et al.The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study[J]. BMC Cancer, 2020,20(1):809. DOI: 10.1186/s12885-020-07309-y. [19] Lei TY, Li J, Zhong H, et al.Postoperative radiotherapy for patients with resectable stage III-N2 non-small cell lung cancer: a systematic review and meta-analysis[J]. Front Oncol, 2021,11:680615. DOI: 10.3389/fonc.2021.680615. [20] Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT meta-analysis trialists group[J]. Lancet, 1998,352(9124):257-263. [21] Wang L, Ye GZ, Xue L, et al.Skip N2 metastasis in pulmonary adenocarcinoma: good prognosis similar to N1 disease[J]. Clin Lung Cancer, 2020,21(5):e423-e434. DOI: 10.1016/j.cllc.2020.02.027. [22] Li SL, Yan S, Lu FL, et al.Validation of the 8th edition nodal staging and proposal of new nodal categories for future editions of the TNM classification of non-small cell lung cancer[J]. Ann Surg Oncol, 2021,28(8):4510-4516. DOI: 10.1245/s10434-020-09461-y. [23] Kim BH, Kim HJ, Wu HG, et al.Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis[J]. Clin Lung Cancer, 2014,15(5):356-364. DOI: 10.1016/j.cllc.2014.05.005. [24] Liu TT, Mu YS, Dang J, et al.The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis[J]. J Cancer, 2019,10(17):3941-3949. DOI: 10.7150/jca.28680. [25] Zhang SY, Wang L, Lu FL, et al.[Correlation between lymph node ratio and clinicopathological features and prognosis of IIIa-N2 non-small cell lung cancer][J]. Zhongguo Fei Ai Za Zhi, 2019,22(11):702-708. DOI: 10.3779/j.issn.1009-3419.2019.11.04. [26] Zheng H, Hu XF, Jiang GN, et al.Define relative incomplete resection by highest mediastinal lymph node metastasis for non-small cell lung cancers: rationale based on prognosis analysis[J]. Lung Cancer, 2011,72(3):348-354. DOI: 10.1016/j.lungcan.2010.10.003. [27] Chun SG, Hu C, Choy H, et al.Impact of intensity- modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial[J]. J Clin Oncol, 2017,35(1):56-62. DOI: 10.1200/JCO.2016.69.1378. [28] Gray JE, Villegas A, Daniel D, et al.Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC[J]. J Thorac Oncol, 2020,15(2):288-293. DOI: 10.1016/j.jtho.2019. 10.002. [29] Betticher DC, Hsu Schmitz SF, Tötsch M, et al.Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial[J]. J Clin Oncol, 2003,21(9):1752-1759. DOI: 10.1200/JCO.2003.11.040. [30] Varlotto JM, Yao AN, DeCamp MM, et al. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival[J]. Int J Radiat Oncol Biol Phys, 2015,91(4):765-773. DOI: 10.1016/j.ijrobp.2014.12.028.
2023, Vol. 32 
